Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock: Insider William Peters Sells 4,139 Shares

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William Peters sold 4,139 shares of the business’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $25.00, for a total value of $103,475.00. Following the transaction, the chief financial officer owned 168,707 shares in the company, valued at approximately $4,217,675. This trade represents a 2.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amphastar Pharmaceuticals Trading Up 5.2%

Amphastar Pharmaceuticals stock opened at $26.27 on Friday. The stock has a 50-day moving average of $21.74 and a two-hundred day moving average of $20.49. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.71 and a current ratio of 2.40. Amphastar Pharmaceuticals, Inc. has a one year low of $16.65 and a one year high of $29.52. The stock has a market cap of $1.12 billion, a PE ratio of 15.54, a price-to-earnings-growth ratio of 4.69 and a beta of 0.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.29. The business had revenue of $183.90 million for the quarter, compared to analyst estimates of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%. On average, research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Engineers Gate Manager LP purchased a new stake in Amphastar Pharmaceuticals in the second quarter valued at $609,000. Squarepoint Ops LLC boosted its stake in shares of Amphastar Pharmaceuticals by 178.0% in the second quarter. Squarepoint Ops LLC now owns 78,795 shares of the company’s stock worth $1,590,000 after buying an additional 50,450 shares during the last quarter. Empowered Funds LLC acquired a new stake in Amphastar Pharmaceuticals during the second quarter worth about $3,286,000. Bank of America Corp DE purchased a new position in Amphastar Pharmaceuticals during the second quarter valued at approximately $2,761,000. Finally, Man Group plc purchased a new position in Amphastar Pharmaceuticals during the second quarter valued at approximately $350,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, July 8th. Wall Street Zen downgraded Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 12th. Bank of America restated an “underperform” rating and issued a $20.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, June 29th. Zacks Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 21st. Finally, Wells Fargo & Company increased their price objective on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Six investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $22.50.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhaled and intranasal products. The company focuses on complex and technically challenging medicines, including products for diabetes, emergency medicine, respiratory conditions and other specialty-care applications.

Its marketed products include glucagon for treating severe hypoglycemia, BAQSIMI nasal glucagon, Primatene MIST for temporary relief of mild intermittent asthma symptoms, naloxone products for opioid overdose emergencies, and enoxaparin sodium injection, an anticoagulant.